<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">emcardio</journal-id><journal-title-group><journal-title xml:lang="ru">Неотложная кардиология и кардиоваскулярные риски</journal-title><trans-title-group xml:lang="en"><trans-title>Emergency Cardiology and Cardiovascular Risks journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2616-633X</issn><publisher><publisher-name>Белорусский государственный медицинский университет</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51922/2616-633X.2022.6.2.1681</article-id><article-id custom-type="elpub" pub-id-type="custom">emcardio-76</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные научные публикации</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Scientific Research</subject></subj-group></article-categories><title-group><article-title>Независимые предикторы гемодинамически осложненного течения раннего послеоперационного периода у пациентов с ИБС: роль современных биомаркеров</article-title><trans-title-group xml:lang="en"><trans-title>Independent predictors of low-cardiac output syndrome in the early postoperative period in CAD patients: the role of modern biomarkers</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шумовец</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shumavets</surname><given-names>V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Минск</p></bio><bio xml:lang="en"><p>Minsk</p></bio><email xlink:type="simple">vshumaviec@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Республиканский научно-практический центр «Кардиология»</institution></aff><aff xml:lang="en"><institution>Republican Scientific and Practical Centre «Cardiology»</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>23</day><month>06</month><year>2025</year></pub-date><volume>6</volume><issue>2</issue><fpage>1681</fpage><lpage>1687</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Шумовец В.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Шумовец В.В.</copyright-holder><copyright-holder xml:lang="en">Shumavets V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://emcardio.bsmu.by/jour/article/view/76">https://emcardio.bsmu.by/jour/article/view/76</self-uri><abstract><p>Применение кардиальных биомаркеров для стратификации риска операций у пациентов кардиохирургического профиля ограничены. С целью изучения прогностической ценности кардиальных биомаркеров (sST2, NT-proBNP, hsTnI, Galectin-3, IL-6 и hsCRP) в открытое проспективное когортное исследование было включено 352 пациента с функциональной ишемической митральной недостаточностью (ИМН) умеренной и выше степени и сниженной сократительной способностью миокарда (ФВ ЛЖ &lt; 40%). Плановое аортокоронарное шунтирование с пластикой митрального клапана выполнено у 239 пациентов (67,9%), с протезированием митрального клапана – у 35 пациентов (9,9%), а в изолированном виде – у 78 пациентов (22,2%). Первичная конечная точка исследования определена, как осложненный послеоперационный период по течению сердечной недостаточности. Критерии гемодинамически осложненного послеоперационного периода отмечены у 80 пациентов (22,7% случаев). Причем развитие синдрома малого сердечного выброса, требующего расширенных лечебных мероприятий, зависело от исходной выраженности ИМН (χ2 = 15,38, p = 0,001). Исходные данные эхокадиографических показателей степени ремоделирования левого желудочка (ЛЖ) не отличались в зависимости от развития или отсутствия гемодинамических осложнений раннего послеоперационного периода (средние КДР ЛЖ – 68,2 мм, КСР ЛЖ – 56,3 мм, иКДО – 118,9 мл/м2 и иКСО – 81,2 мл/м2, p &gt; 0,05). На дооперационном этапе значения маркеров sST2, NT-proBNP, Galectin-3, hsTnI, CRP и IL-6 были достоверно выше (p &lt; 0,001) у пациентов, у которых ранний послеоперационный период протекал с гемодинамическими осложнениями. При изолированном превышении NT-proBNP &gt; 2136 пг/мл, осложненный период отмечен в 24,6% случаев, при изолированном превышении sST2 &gt; 35,8 нг/мл – в 44,4% случаев, а при сочетанном повышении пороговых значений и sST2, и NT-proBNP – у 59,3% пациентов (χ2 = 71,67, р = 0,001). При оценке диагностической способности различных предикторов риска площадь под ROC-кривой максимальная при включении в модель прогнозирования исходных значений обоих биомаркеров sST2 и NT-proBNP (0,792, 95% ДИ 0,709–0,846), что достоверно больше, чем при использовании биомаркеров по отдельности (p &lt; 0,05).</p></abstract><trans-abstract xml:lang="en"><p>Cardiac biomarkers are recommended to stratify the risk of surgery in general surgical practice, but their adoption in cardiac surgery patients is limited. The aim of our study is assessing the prognostic possibility and predictive significance of modern cardiac-specific biomarkers (NT-proBNP, sST-2, hsTn-I, Galectin-3, hsCRP and IL-6) in the determining of patient-oriented treatment strategies. In the open prospective cohort study 352 patients with moderate or severe functional ischemic mitral regurgitation (IMR) were included. The inclusion criteria in the study were the reduced myocardial contractility (LV EF &lt; 40%) in chronic CAD patients. CABG combined with mitral valve repair was performed in 239 patients (67.9%), mitral valve replacement in 35 patients (9.9%), and isolated in 78 patients (22.2%). The primary end-point of the study was defined as a complicated postoperative period with worsening of heart failure. Complicated postoperative period has been registered in 80 patients (22.7% of cases). The complicated early postoperative period did not relate to surgical strategies (χ2 = 0.398, p = 0.528). We didn’t find any difference in the degree of left ventricle (LV) remodeling between patients with complicated or not postoperative course (mean LV EDD – 68.2 mm, LV ESD – 56.3 mm, iEDV – 118.9 ml/m2 and iESV – 81.2 ml/m2, p &gt; 0.05). By contrast, all of the used pre-operative biomarker tests differed in the examined groups of patients (p &lt; 0,001). The complicated postoperative course was observed in 24.6% of cases with isolated elevation of NT-proBNP &gt; 136 pg/ml, in 44.4% of cases with isolated elevation of sST2 &gt; 35.8 ng/ml, and 59.3% of cases in combined increase in thresholds and sST2 and NT-proBNP (χ2 = 71.67, p = 0.001). The highest quality of the model and the estimate forecast of the postoperative low-output syndrome was measured for sST2 and NT-proBNP biomarkers (AUC = 0,792, 95% CI 0,709–0,846). The inclusion of both thresholds of sST2 and NT-proBNP retained their reliable influence on the forecast, with the model showed a high level of consent (79.7% of correctly recognized cases).</p></trans-abstract><kwd-group xml:lang="ru"><kwd>Кардиохирургия</kwd><kwd>Кардиальные биомаркеры</kwd><kwd>ST-2</kwd><kwd>NT-pro BNP</kwd><kwd>Предикторы клинических исходов</kwd><kwd>Проспективные исследования</kwd><kwd>Оценка риска</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Cardiac surgery</kwd><kwd>Cardiac biomarkers</kwd><kwd>ST-2</kwd><kwd>NT-pro BNP</kwd><kwd>Clinical prediction rule</kwd><kwd>Prospective studies</kwd><kwd>Risk assessment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mebazaa, A., Pitsis, A. A., Rudiger, A., et al (2010). Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Critical care (London, England), 14(2), 201-215. https://doi.org/10.1186/cc8153</mixed-citation><mixed-citation xml:lang="en">Mebazaa, A., Pitsis, A. A., Rudiger, A., et al (2010). Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Critical care (London, England), 14(2), 201-215. https://doi.org/10.1186/cc8153</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Nashef, S. A., Roques, F., Sharples, L. D., Nilsson, J., Smith, C., Goldstone, A. R., &amp; Lockowandt, U. (2012). EuroSCORE II. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 41(4), 734–745. https://doi.org/10.1093/ejcts/ezs043</mixed-citation><mixed-citation xml:lang="en">Nashef, S. A., Roques, F., Sharples, L. D., Nilsson, J., Smith, C., Goldstone, A. R., &amp; Lockowandt, U. (2012). EuroSCORE II. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 41(4), 734–745. https://doi.org/10.1093/ejcts/ezs043</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., … Touyz, R. M. (2022). 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. European heart journal, 43(39), 3826–3924. https://doi.org/10.1093/eurheartj/ehac270.</mixed-citation><mixed-citation xml:lang="en">Halvorsen, S., Mehilli, J., Cassese, S., Hall, T. S., … Touyz, R. M. (2022). 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. European heart journal, 43(39), 3826–3924. https://doi.org/10.1093/eurheartj/ehac270.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Dolapoglu, A., Avci, E., Yildirim, T., Kadi, H., &amp; Celik, A. (2019). Using Soluble ST2 to Predict Adverse Postoperative Outcomes in Patients with Impaired Left Ventricular Function Undergoing Coronary Bypass Surgery. Medicina (Kaunas, Lithuania), 55(9), 572. https://doi.org/10.3390/medicina55090572</mixed-citation><mixed-citation xml:lang="en">Dolapoglu, A., Avci, E., Yildirim, T., Kadi, H., &amp; Celik, A. (2019). Using Soluble ST2 to Predict Adverse Postoperative Outcomes in Patients with Impaired Left Ventricular Function Undergoing Coronary Bypass Surgery. Medicina (Kaunas, Lithuania), 55(9), 572. https://doi.org/10.3390/medicina55090572</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Patel, D. M., Thiessen-Philbrook, H., Brown, J. R., McArthur, E., Moledina, D. G., Mansour, S. G., Shlipak, M. G., Koyner, J. L., Kavsak, P., Whitlock, R. P., Everett, A. D., Malenka, D. J., Garg, A. X., Coca, S. G., &amp; Parikh, C. R. (2020). Association of plasmasoluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. American heart journal, 220, 253–263. https://doi.org/10.1016/j.ahj.2019.11.014</mixed-citation><mixed-citation xml:lang="en">Patel, D. M., Thiessen-Philbrook, H., Brown, J. R., McArthur, E., Moledina, D. G., Mansour, S. G., Shlipak, M. G., Koyner, J. L., Kavsak, P., Whitlock, R. P., Everett, A. D., Malenka, D. J., Garg, A. X., Coca, S. G., &amp; Parikh, C. R. (2020). Association of plasmasoluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. American heart journal, 220, 253–263. https://doi.org/10.1016/j.ahj.2019.11.014</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ramkumar, N., Jacobs, J. P., Berman, R. B., Parker, D. M., MacKenzie, T. A., Likosky, D. S., DiScipio, A., Malenka, D. J., &amp; Brown, J. R. (2019). Cardiac Biomarkers Predict Long-term Survival After Cardiac Surgery. The Annals of thoracic surgery, 108(6), 1776–1782. https://doi.org/10.1016/j.athoracsur.2019.04.123</mixed-citation><mixed-citation xml:lang="en">Ramkumar, N., Jacobs, J. P., Berman, R. B., Parker, D. M., MacKenzie, T. A., Likosky, D. S., DiScipio, A., Malenka, D. J., &amp; Brown, J. R. (2019). Cardiac Biomarkers Predict Long-term Survival After Cardiac Surgery. The Annals of thoracic surgery, 108(6), 1776–1782. https://doi.org/10.1016/j.athoracsur.2019.04.123</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Heidenreich, P. A., Bozkurt, B., Aguilar, D., … Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), 1757–1780. ht tps://doi.org/10.1016/j.jacc.2021.12.011</mixed-citation><mixed-citation xml:lang="en">Heidenreich, P. A., Bozkurt, B., Aguilar, D., … Yancy, C. W. (2022). 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 79(17), 1757–1780. ht tps://doi.org/10.1016/j.jacc.2021.12.011</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Taub, P. R., Daniels, L. B., &amp; Maisel, A. S. (2009). Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation. Heart failure clinics, 5(2), 169–175. https://doi.org/10.1016/j.hfc.2008.11.009</mixed-citation><mixed-citation xml:lang="en">Taub, P. R., Daniels, L. B., &amp; Maisel, A. S. (2009). Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation. Heart failure clinics, 5(2), 169–175. https://doi.org/10.1016/j.hfc.2008.11.009</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
